The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury
Autor: | Fabio Ius, Christopher A Hinze, Jawad Salman, Stefan G. Tullius, Jasper Iske, Axel Haverich |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Ischemia Primary Graft Dysfunction Inflammation Article Internal medicine medicine Humans Immunology and Allergy Lung transplantation Pharmacology (medical) Lung Transplantation business.industry Ex vivo lung perfusion Organ Preservation respiratory system medicine.disease Perfusion Clinical trial medicine.anatomical_structure Reperfusion Injury Cardiology medicine.symptom business Reperfusion injury Lung Transplantation |
Zdroj: | Am J Transplant |
ISSN: | 1600-6135 |
Popis: | Allogeneic lung transplantation (LuTx) is considered the treatment of choice for a broad range of advanced, progressive lung diseases resistant to conventional treatment regimens. Ischemia reperfusion injury (IRI) occurring upon reperfusion of the explanted, ischemic lung during implantation remains a crucial mediator of primary graft dysfunction (PGD) and early allo-immune responses. Ex vivo lung perfusion (EVLP) displays an advanced technique aiming at improving lung procurement and preservation. Indeed, previous clinical trials have demonstrated a reduced incidence of PGD following LuTx utilizing EVLP, while long-term outcomes are yet to be evaluated. Mechanistically, EVLP may alleviate donor lung inflammation through reconditioning the injured lung and diminishing IRI through storing the explanted lung in a non-ischemic, perfused, and ventilated status. In this work, we review potential mechanisms of EVLP that may attenuate IRI and improve organ quality. Moreover, we dissect experimental treatment approaches during EVLP that may further attenuate inflammatory events deriving from tissue ischemia, shear forces or allograft rejection associated with LuTx. |
Databáze: | OpenAIRE |
Externí odkaz: |